Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome [0.03%]
随机SAFIR02-LUNG试验中伴或不伴脑转移的非小细胞肺癌患者的分子分型及与颅内结果的相关性研究
Alice Mogenet,Fabrice Barlesi,Benjamin Besse et al.
Alice Mogenet et al.
Introduction: Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several mechanis...
Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon [0.03%]
EGFR/ALK野生型或TKI初治非小细胞肺癌向神经内分泌癌转化的临床特征及预后研究——一个被忽视的现象
Xiao Chu,Yuyin Xu,Ye Li et al.
Xiao Chu et al.
Introduction: Neuroendocrine transformation (NET) is a resistance mechanism for epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSC...
Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72] [0.03%]
“基于两项随机EORTC试验的肺癌或恶性胸膜间皮瘤患者的EORTC QLQ-C30量表最小临床重要变化值的解读指导”的勘误(2022年放射肿瘤学第171卷)
Michael Koller,Jammbe Z Musoro,Krzysztof Tomaszewski et al.
Michael Koller et al.
Published Erratum
Lung cancer (Amsterdam, Netherlands). 2022 Sep:171:126. DOI:10.1016/j.lungcan.2022.05.006 2022
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy [0.03%]
与真实世界疗法相比， Amivantamab治疗铂类化疗后疾病进展的携带EGFR 20号外显子插入突变的晚期非小细胞肺癌患者中的疗效
Anna Minchom,Santiago Viteri,Lyudmila Bazhenova et al.
Anna Minchom et al.
Background: In the single-arm CHRYSALIS study, amivantamab showed durable responses and manageable safety in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon...
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils [0.03%]
Smarca4缺陷型肺癌是一种高度浸润FOXP3+细胞和中性粒细胞的侵袭性肿瘤
Yoan Velut,Elise Decroix,Hélène Blons et al.
Yoan Velut et al.
Introduction: SMARCA4/BRG1 loss of expression occurs in 5-10% of non-small cell lung carcinomas (NSCLC). We investigated the pathological, molecular and immune environment characteristics of this deficiency among NSCLC, i...
Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung - Determination and validation of optimal prognostic cut-offs [0.03%]
肿瘤细胞芽生和通过肺鳞状细胞癌的气腔扩散-确定并验证最佳预后截断值
Fabian Stögbauer,Manuela Lautizi,Mark Kriegsmann et al.
Fabian Stögbauer et al.
Purpose: Prognostic stratification of patients with squamous cell carcinomas of the lung (SCC-L) is challenging. Therefore, we investigated several histomorphological parameters (tumour cell budding (TCB), spread through ...
Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel [0.03%]
利用特定于肺癌的Ultra SEEK癌基因面板分析呼出气冷凝液（EBC）中的循环肿瘤DNA（ctDNA）
Daniel J Ryan,Sinead Toomey,Robert Smyth et al.
Daniel J Ryan et al.
Introduction: Small diagnostic tissue samples can be inadequate in testing an expanding list of validated oncogenic driver alterations and fail to reflect intratumour heterogeneity (ITGH) in lung cancer. Liquid biopsies a...
Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey [0.03%]
欧洲一项关于非小细胞肺癌患者的疾病负担及治疗倾向的调查结果
Amanda Tufman,Kathy Redmond,Andromachi Giannopoulou et al.
Amanda Tufman et al.
Objectives: To understand European non-small cell lung cancer (NSCLC) patients' perceptions of disease burden, treatment, and future expectations of treatment and care. ...
Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma [0.03%]
手术切除的肺腺癌中PD-L2表达的临床意义
Kazuya Takamochi,Kieko Hara,Takuo Hayashi et al.
Kazuya Takamochi et al.
Objectives: Programmed death ligand 1 and 2 (PD-L1 and PD-L2) bind programmed death 1 (PD-1). PD-L1 is an established predictive biomarker of response to immunotherapies targeting PD-1 and PD-L1 in lung adenocarcinoma (LU...
The reporting of pulmonary nodule results by letter in a lung cancer screening setting [0.03%]
肺癌筛查环境下通过信函报告肺结节结果
Jennifer L Dickson,Amyn Bhamani,Samantha L Quaife et al.
Jennifer L Dickson et al.
Objectives: Pulmonary nodules are commonly found in Lung Cancer Screening (LCS), with results typically communicated by face-to-face or telephone consultation. Providing LCS on a population basis requires resource efficie...
Observational Study
Lung cancer (Amsterdam, Netherlands). 2022 Jun:168:46-49. DOI:10.1016/j.lungcan.2022.04.009 2022